Petros Pharmaceuticals Inc PTPI is trading higher Wednesday after the company announced 476% growth year-over-year of STENDRA tablet sales as part of its digital marketing agreement with Hims & Hers Health Inc HIMS.
The companies also announced the availability of additional dosages of STENDRA through the Hims & Hers platform, further expanding the partnership.
"Our continued relationship with Hims supports an industry-leading telehealth platform that allows individuals to inquire about and address erectile dysfunction with discretion and by way of a convenient method of healthcare engagement," said Fady Boctor, president and chief commercial officer of Petros Pharmaceuticals.
"With significant growth year-over-year of STENDRA tablet sales through Hims, we are excited to expand our collaboration with Hims and enhance access to STENDRA through this critical channel," Boctor added.
Petros Pharmaceuticals is a men's health pharmaceutical company focused on identifying, developing, acquiring and commercializing innovative therapeutics for men's health issues including erectile dysfunction, peyronie's disease, hormone health and substance use disorders.
PTPI Price Action: Petros Pharmaceuticals has traded as high as $5.95 and as low as $1.56 over a 52-week period.
The stock was up 56.6% at $2.74 at time of publication.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
